- MITI Stock Page
Micromet Inc. (NASDAQ:MITI)
Last Update: 5 hours ago
| Change: | 0.27 (4.38%) |
| Last Trade: | 6.49 |
| Prev Close: | 6.22 |
| Share Volume: | 513,778 |
| Market Cap: | 278.04M |
| EPS (Earnings per share): | -0.48 |
| P/E (Price/earning ratio): | N/A |
| P/B (Price/book ratio): | 13.24 |
| Stock Price History | |
|---|---|
| Beta: | 0.40 |
| 52 week change: | 233.80% |
| 52 week high: | 7.74 |
| 52 week low: | 1.22 |
| 50 day moving avarage: | 4.29 |
| 200 day moving avarage: | 2.64 |
| Dividends | |
| Ex dividend date: | N/A |
| Dividend yield: | N/A |
| Dividend rate: | N/A |
| Share Statistics | |
| Avarage 10 day volume: | 881,923 |
| Shares outstanding: | 40,828,759 |
| Short interest date: | Aug 12, 2008 |
| Short shares: | 417,689 |
| Short ratio: | 1.90 |
| Short % of float: | 1.30% |
Thu, 28 Aug 2008 6:15 PM
After-Hours:
6.29
-0.20 (-3.08%)
| Today | 5d | 1m | 3m | 6m | 1y | 5y |
Latest Headlines for MITI
Company Profile
Sector: Healthcare
Industry: Drugs
We are a biotechnology company
A biopharmaceutical company, which is engaged in developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases.
MITI Headlines
-
Aug 18 at 7:01 ET
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE -
Aug 14 at 2:01 ET
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab -
Aug 07 at 7:00 ET
Micromet, Inc. Reports Second Quarter 2008 Financial Results -
Jul 29 at 7:00 ET
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results -
Jun 24 at 7:00 ET
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases -
Jun 12 at 7:00 ET
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia -
Jun 05 at 7:30 ET
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma -
May 22 at 2:45 ET
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas -
May 08 at 7:01 ET
Micromet, Inc. Reports First Quarter 2008 Financial Results -
May 02 at 4:51 ET
Micromet, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2008 Financial Results
